

Park SunHyun<sup>o</sup>, Shin DongYun, Lee DoSang, Suh YoungGer

College of Pharmacy, Seoul National University, San 56-1, Shinrim-Dong, Kwanak-Gu, Seoul 151-742, Korea

During the last two decades, the increasing prevalence of antibiotic-resistant bacteria has had an enormous impact on infection control policies. In particular, the resistances to multiple antibiotics of strains of Gram-positive Staphylococci, methicillin-resistant Staphylococcus aureus (MRSA), are now significant clinical problem. Even though vancomycin and teicoplanin, a class of glycopeptide antibiotics, are widely used clinically in the treatment of MRSA infections, the structural complexity and toxic side effects of these antibiotics have prompted increased efforts to find and investigate new and effective antibiotics.

Towards this end, we have recently reported the isolation of a potent anti-MRSA sesquiterpenoid ortho-quinone, mansonone F, from the Korean medicinal plant which has traditionally been used to treat infectious diseases. It has been shown to have antibacterial activities against Gram-positive bacteria and, in particular, MRSA (with an MIC<sub>90</sub> of 2 mg/ml in vitro), comparable to vancomycin. Mansonone F is structurally simple and unique ortho-naphthoquinone with conjugated tricyclic ring skeleton, and its energy-minimized structure turned out to be complete flat and highly strained.

In continuation of pharmacophore identification and investigation into the structure-anti-MRSA activity relationship of sesquiterpenoids based on the natural mansonone F, the systemically modified analogues of mansonone F were synthesized and assayed against MRSA strains.

Consequently, we have established the partial structure-activity relationship of mansonone F.

[PD1-22] [ 10/19/2001 (Fri) 14:00 - 17:00 / Hall D ]

### **Synthesis and in vitro Antibiotic Activity of C-9 modified Derivatives of Erythromycin A.**

Kwon JinSun<sup>o</sup>, Ryu JungSu, Park CheonHo, Kang JaeHoon, Kim KeeWon

Research Laboratories, ILDONG Pharmaceutical Co., Ltd

Since its discovery by Mcgurie et al. in 1952, erythromycin A (EM-A) has been the most widely used against many diseases, owing to its safety and effectiveness, especially respiratory tract infections. A major drawback to erythromycin is its instability in the acidic medium of the stomach. To minimize the acid instability and improve the activity, C-9 modified derivatives of erythromycin A were designed. The improvement of activity of erythromycin 9-oxime against gram-positive bacteria by introducing phenyl groups and isoxazole groups into the aliphatic chain was attempted. And also phenyl substituents were introduced at the C-9 position of erythromycin for forming C=C bond instead of C=O bond. Thus, prepared antibiotics were evaluated biologically by measuring the minimum inhibitory concentrations (MIC) against various bacterial strains. This new class of macrolide antibiotics showed reduced MIC value compared with those of erythromycin A and clarithromycin.

[PD1-23] [ 10/19/2001 (Fri) 14:00 - 17:00 / Hall D ]

### **Lupane Derivatives Bearing Aminoacetyl Moiety**

You YoungJae<sup>o</sup>, Kim Yong, Nam NguyenHai, Ahn ByungZun

충남대학교 약학대학

Lupane derivatives showed good cytotoxic activity and it was reported that their cytotoxic activity mainly